TinyGemsBreaks Archive - Page 122 of 124

MondayJun 06, 2022 1:11 pm

TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Releases Q4, FY 2021 Financial Report; Announces Partnership with Onassis Holdings (ONSS)

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS (“SaaS”) platform, is reporting record financial numbers for fiscal year 2021 and Q4 2021. Highlights of the report show that SRA exceeded 2021 guidance of $31.5 million, totaling $28.6 million in revenue with BIGtoken, its former subsidiary, totaling $3.4 million in revenue, and record quarterly revenue of $9.6 million, a 27% increase from the company’s Q3 report and 170% over the previous year period. In addition, SRAX reported record GAAP operating income of $2 million in 2021 compared to a…

MondayJun 06, 2022 12:45 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Has Reached Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that Adelia Therapeutics Inc., its wholly owned subsidiary, has achieved significant milestones, which the company identified as Y2, Q2 (i), (vi), Y2, Q3 (ii), Year 2 Q4 (i) and Year 3 Q1 (i), (ii). These milestones are outlined in the Dec. 4, 2021, contribution agreement between Cybin and Adelia; the agreement specifies what actions are to be taken when these milestones are reached. Specifically, when these milestones are met, the agreement calls for class B common shares to be issued to Adelia shareholders; those shares are…

FridayJun 03, 2022 2:55 pm

TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Announces Details for 2022 LD Micro Invitational

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced details for the 2022 LD Micro Invitational. SRAX will host the prominent investor conference on June 7-9 at the Four Seasons Hotel Westlake Village, as well as via its Sequire Virtual Events platform. LD Micro is the host of the most influential conferences in the small-cap world. Following last October’s success of the LD Micro Main Event, SRAX is providing a virtual option for those unable to attend the physical conference. The event, which expects to…

FridayJun 03, 2022 2:47 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Announces Strong Q2 Financial Results

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, today announced financial results for its second fiscal quarter ended April 30, 2022. Among the highlights, the company reported Q2 revenues of $8,482,743, a 221% increase as compared to the same quarter last year. The company also noted 15 consecutive quarters of profitability. “We are pleased with the financial results of our second quarter as a company with both B2B and B2C verticals,” said Golden Matrix CEO Brian Goodman. “During the quarter we implemented upgraded technology and stronger accounting controls to improve cash…

FridayJun 03, 2022 2:25 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awards Exclusive License to Japan’s Premier Wellness Science Co.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co. Ltd. LEXX announced that Premier is purchasing exclusive rights to DehydraTECH technology for the Japanese nonpharmaceutical market; the company will use the tech in oral liquid and nonliquid products, as well as for topical, hair-care, lip-care and cosmetics products. According to the announcement, Lexaria will receive minimum payments of $4,527,500 over the next five years, as all well as royalties from the sales of products…

FridayJun 03, 2022 2:00 pm

TinyGemsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model,” the article appears in the June 2, 2022, issue of the publication, which is the largest journal in the field of psychology. The article discusses EMBARK’s…

FridayJun 03, 2022 1:39 pm

TinyGemsBreaks — Mullen Automotive Inc. (NASDAQ: MULN) CEO to Appear on Benzinga’s ‘All Access’ Series

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, and its CEO and chair David Michery are spotlighted during an interview on Benzinga’s All Access Series. The interview is slated for today, June 3, 2022, at 11 a.m. ET. Michery and All Access host Spencer Israel will discuss the company, including its upcoming “Strikingly Different” U.S. test drive tour, which will include stops at 19 cities across the country. Benzinga’s All Access show is a valuable source for those who want to learn more about the latest-trending stocks and investment opportunities. The show features live CEO interviews, due diligence…

ThursdayJun 02, 2022 1:38 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH Footprint Extends to Europe with License Granted to Valcon Medical

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in the European and United Kingdom markets. The company awarded the nonexclusive licenses to Valcon Medical A/S, a European contract manufacturing organization that specializes in the manufacturing of medical cannabis extracts for the EU and UK. According to the announcement, Lexaria will receive milestone fees and royalty payments from sales of products manufactured by Valcon.Valcon products will include an array of options, from nonregistered medical products through magistral programs to country-level market-authorized medical cannabis products through pilot programs; they will…

ThursdayJun 02, 2022 12:34 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will host a virtual Key Opinion Leader webinar from 11:00 a.m. to 12:00 p.m. ET on Thursday, June 9, 2022. The webinar will be moderated by Cybin’s Chief Executive Officer Doug Drysdale and will feature two leading experts for a discussion on the psychedelics landscape and current and emerging psychedelic-based therapeutics. Dr. John Krystal, the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of…

ThursdayJun 02, 2022 11:35 am

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces $5M Registered Direct and Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced its entry into securities purchase agreements with a single health care-focused institutional investor for the issuance and sale of 4,079,256 of its common shares, each at a purchase price of $0.858 (or pre-funded warrant in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, InMed has also agreed to issue and sell to the investor 1,748,250 common shares (or pre-funded warrant in lieu thereto) at the same purchase price as in…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks